HRP20121036T1 - Intranazalni spojevi - Google Patents
Intranazalni spojevi Download PDFInfo
- Publication number
- HRP20121036T1 HRP20121036T1 HRP20121036AT HRP20121036T HRP20121036T1 HR P20121036 T1 HRP20121036 T1 HR P20121036T1 HR P20121036A T HRP20121036A T HR P20121036AT HR P20121036 T HRP20121036 T HR P20121036T HR P20121036 T1 HRP20121036 T1 HR P20121036T1
- Authority
- HR
- Croatia
- Prior art keywords
- poloxamer
- formulation
- apomorphine
- formulation according
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Tekuća vodena formulacija za intranazalno davanje apomorfina, koja sadrži:
(a) barem 15 mg/ml apomorfina; i
(b) barem jedan kopolimer polioksietilen-polioksipropilena (poloksamer) kao solubilizirajući agens, pri čemu poloksamer ima prosječnu molekulsku masu od 9,7000 Da ili nižu i ima opću formulu:
HO(C2H4O)a(C3H6O)b(C2H4O)aH, pri čemu je a od 2 do 90 i b je od 15 do 40.
2. Formulacija prema patentnom zahtjevu 1, koja sadrži barem 20 mg/ml apomorfina.
3. Formulacija prema patentnom zahtjevu 2, koja sadrži od 25 do 60 mg/ml apomorfina.
4. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je poloksamer Poloxamer 124, Poloxamer 188 ili Poloxamer 237.
5. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je poloksamer prisutan u količini od 50 do 250 mg/ml.
6. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, koja sadrži od 20 do 40 mg/ml HCl apomorfina i od 100 do 200 mg/ml poloksamera 188.
7. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, koja sadrži antioksidant.
8. Uređaj za nazalno davanje lijeka ili dozni uložak za upotrebu u uređaju za nazalno davanje lijeka napunjen sa formulacijom definiranom u bilo kojem od patentnih zahtjeva 1 do 7.
9. Formulacija definirana prema bilo kojem od patentnih zahtjeva 1 do 7 za upotrebu u intranazalnom davanju apomorfina pacijentu kojem je to potrebno.
10. Formulacija prema patentnom zahtjevu 9 za upotrebu u liječenju i/ili kontroli Parkinsonove bolesti ili upotrebu u liječenju i/ili kontroli erektilne disfunkcije.
11. Upotreba formulacije prema patentnom zahtjevu 1 u proizvodnji lijeka za liječenje i/ili kontrolu Parkinsonove bolesti ili u proizvodnji lijeka za liječenje i/ili kontrolu erektilne disfunkcije.
12. Uređaj prema patentnom zahtjevu 8, koji obuhvaća bocu koja sadrži formulaciju definiranu u bilo kojem od patentnih zahtjeva 1 do 7 na koju je montirana pumpa za raspršivanje (sprej pumpa).
13. Komplet koji se sastoji od (i) formulacije prema bilo kojem od patentnih zahtjeva 1 do 7 zapečaćene u staklenoj boci ili bočici i (ii) nazalne pumpe za raspršivanje (sprej pumpe).
14. Komplet prema patentom zahtjevu 13, pri čemu je formulacija prema bilo kojem od patentnih zahtjeva 1 do 7 zapečaćena u bocu ili bočicu sa dušičnim prepunjenjem.
15. Postupak za dobijanje kompozicije prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu postupak obuhvaća (a) minimiziranje sadržaja otopljenog kisika u vodi; (b) rastvaranje poloksamera u vodi dobivenoj u stupnju (a); (c) dodavanje apomorfina u proizvod iz stupnja (b) i rastvaranje apomorfina; (d) prilagođavanje pH proizvoda iz stupnja (c) kada je potrebno i dovođenje formulacije do krajnje težine ili zapremine sa vodom dobijenom u stupnju (a); i (e) premještanje proizvoda iz stupnja (d) u posudu i pečaćenje u atmosferi dušika.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07254426A EP2057982A1 (en) | 2007-11-09 | 2007-11-09 | Intranasal compositions |
| PCT/GB2008/003782 WO2009060226A1 (en) | 2007-11-09 | 2008-11-10 | Intranasal compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121036T1 true HRP20121036T1 (hr) | 2013-01-31 |
Family
ID=39052379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121036AT HRP20121036T1 (hr) | 2007-11-09 | 2008-11-10 | Intranazalni spojevi |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8309108B2 (hr) |
| EP (2) | EP2057982A1 (hr) |
| JP (1) | JP5530931B2 (hr) |
| KR (1) | KR101522529B1 (hr) |
| CN (1) | CN101883555B (hr) |
| AU (1) | AU2008326220B2 (hr) |
| BR (1) | BRPI0819115A2 (hr) |
| CA (1) | CA2705153C (hr) |
| CY (1) | CY1113824T1 (hr) |
| DK (1) | DK2214640T3 (hr) |
| ES (1) | ES2398267T3 (hr) |
| HR (1) | HRP20121036T1 (hr) |
| MX (1) | MX2010005013A (hr) |
| NZ (1) | NZ585107A (hr) |
| PL (1) | PL2214640T3 (hr) |
| PT (1) | PT2214640E (hr) |
| SI (1) | SI2214640T1 (hr) |
| TW (1) | TWI426928B (hr) |
| WO (1) | WO2009060226A1 (hr) |
| ZA (1) | ZA201003172B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3456315A1 (en) * | 2012-06-05 | 2019-03-20 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| CN104602675B (zh) | 2012-06-21 | 2019-06-28 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
| GB201217419D0 (en) * | 2012-09-28 | 2012-11-14 | Innotesto Bvba | Improvements in or relating to oromucosal apomorphine compositions |
| EP3021832B9 (en) * | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| MX375936B (es) | 2013-12-04 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmaceuticas mejoradas de pimobendan. |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| JP2022543803A (ja) * | 2019-08-07 | 2022-10-14 | アクリプス ワン インコーポレイテッド | （６ａＳ）－６－メチル－５，６，６ａ，７－テトラヒドロ－４Ｈ－ジベンゾ［ｄｅ，ｇ］キノリン－１０，１１－ジオールの医薬組成物 |
| GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
| CN115804754A (zh) * | 2022-12-16 | 2023-03-17 | 广州新济药业科技有限公司 | 吗啡鼻喷剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9103824D0 (en) * | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
| AU6428894A (en) | 1993-03-26 | 1994-10-24 | Franciscus W.H.M. Merkus | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
| GB9416884D0 (en) | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
| EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
| GB9713980D0 (en) | 1997-07-03 | 1997-09-10 | Danbiosyst Uk | New conjugates |
| ATE303131T1 (de) * | 1997-12-02 | 2005-09-15 | Archimedes Dev Ltd | Zusammensetzungen zur nasalen verabreichung |
| US6436950B1 (en) | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) * | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| GB0403938D0 (en) * | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
-
2007
- 2007-11-09 EP EP07254426A patent/EP2057982A1/en not_active Withdrawn
-
2008
- 2008-11-07 TW TW097143029A patent/TWI426928B/zh not_active IP Right Cessation
- 2008-11-10 JP JP2010532658A patent/JP5530931B2/ja not_active Expired - Fee Related
- 2008-11-10 SI SI200830875T patent/SI2214640T1/sl unknown
- 2008-11-10 MX MX2010005013A patent/MX2010005013A/es active IP Right Grant
- 2008-11-10 DK DK08847366.5T patent/DK2214640T3/da active
- 2008-11-10 AU AU2008326220A patent/AU2008326220B2/en not_active Ceased
- 2008-11-10 PT PT88473665T patent/PT2214640E/pt unknown
- 2008-11-10 ES ES08847366T patent/ES2398267T3/es active Active
- 2008-11-10 PL PL08847366T patent/PL2214640T3/pl unknown
- 2008-11-10 BR BRPI0819115-8A patent/BRPI0819115A2/pt not_active IP Right Cessation
- 2008-11-10 EP EP08847366A patent/EP2214640B1/en not_active Not-in-force
- 2008-11-10 HR HRP20121036AT patent/HRP20121036T1/hr unknown
- 2008-11-10 KR KR1020107011658A patent/KR101522529B1/ko not_active Expired - Fee Related
- 2008-11-10 CN CN200880115432XA patent/CN101883555B/zh not_active Expired - Fee Related
- 2008-11-10 NZ NZ585107A patent/NZ585107A/en not_active IP Right Cessation
- 2008-11-10 CA CA2705153A patent/CA2705153C/en not_active Expired - Fee Related
- 2008-11-10 US US12/741,932 patent/US8309108B2/en not_active Expired - Fee Related
- 2008-11-10 WO PCT/GB2008/003782 patent/WO2009060226A1/en active Application Filing
-
2010
- 2010-05-05 ZA ZA2010/03172A patent/ZA201003172B/en unknown
-
2013
- 2013-01-23 CY CY20131100059T patent/CY1113824T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2214640B1 (en) | 2012-10-24 |
| KR20100094980A (ko) | 2010-08-27 |
| SI2214640T1 (sl) | 2013-02-28 |
| EP2057982A1 (en) | 2009-05-13 |
| BRPI0819115A2 (pt) | 2015-07-07 |
| TWI426928B (zh) | 2014-02-21 |
| MX2010005013A (es) | 2010-05-27 |
| US8309108B2 (en) | 2012-11-13 |
| PT2214640E (pt) | 2013-01-16 |
| JP5530931B2 (ja) | 2014-06-25 |
| US20100249170A1 (en) | 2010-09-30 |
| DK2214640T3 (da) | 2013-02-04 |
| CA2705153C (en) | 2016-05-24 |
| CA2705153A1 (en) | 2009-05-14 |
| AU2008326220B2 (en) | 2013-05-23 |
| WO2009060226A1 (en) | 2009-05-14 |
| ES2398267T3 (es) | 2013-03-15 |
| AU2008326220A2 (en) | 2010-11-04 |
| AU2008326220A1 (en) | 2009-05-14 |
| ZA201003172B (en) | 2012-10-31 |
| KR101522529B1 (ko) | 2015-05-26 |
| EP2214640A1 (en) | 2010-08-11 |
| JP2011503044A (ja) | 2011-01-27 |
| CY1113824T1 (el) | 2016-07-27 |
| HK1146711A1 (en) | 2011-07-08 |
| CN101883555B (zh) | 2012-07-11 |
| PL2214640T3 (pl) | 2013-03-29 |
| NZ585107A (en) | 2012-05-25 |
| TW200936179A (en) | 2009-09-01 |
| CN101883555A (zh) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121036T1 (hr) | Intranazalni spojevi | |
| ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
| CN103476397B (zh) | 一种制备用于注射的含培美曲塞或其盐的无抗氧化剂溶液形式的药物制剂的方法 | |
| TW200812643A (en) | Gel-type formulation for spray adherable to skin/mucosa and administration system thereof | |
| TWI746662B (zh) | 眼科用製品及黏度降低抑制方法 | |
| HRP20161100T1 (hr) | Sastav injektibilnog antipsihotika u depo obliku | |
| CN104812392B (zh) | 稳定的培美曲塞制剂 | |
| IL223488A (en) | Injectable flow bar preparation containing buprenorphine | |
| HRP20191994T1 (hr) | Formulacije ketorolaka spremne za uporabu | |
| HRP20170270T1 (hr) | Metoda davanja plućnog surfaktanta | |
| SI2648520T1 (en) | Formulation of dexmedetomidine pre-mixtures | |
| JP2011503044A5 (hr) | ||
| CN104010661A (zh) | 含有二丁基羟基甲苯的制剂及二丁基羟基甲苯的稳定化方法 | |
| HRP20200704T1 (hr) | Vodena formulacija koja sadrži paracetamol i ibuprofen | |
| EP2170399A1 (en) | Intranasal administration of asenapine and pharmaceutical compositions therefor | |
| UA102187C2 (ru) | Фармацевтическая композиция для пероральной доставки дииндолилметана | |
| HRP20130150T1 (hr) | Sustav pakiranja farmaceutskih sastava i komplet za intravenozno davanje | |
| HRP20120483T1 (hr) | Formulacije peg interferona beta | |
| CN101969926A (zh) | 拓扑替康即用溶液 | |
| CN102958519B (zh) | 包含扑热息痛的药物组合物及其制备方法 | |
| CN106132416A (zh) | 注射液制剂及其制造方法 | |
| MX2013014519A (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. | |
| TWI546087B (zh) | Containing aqueous preparations of acetaminophen and ibuprofen | |
| CN102671182A (zh) | 一种用于鼻腔给药的含地加瑞克的药物组合物及制备方法 | |
| WO2024026463A1 (en) | Composition for nasal delivery of an active compound |